Myocardial Metabolic Flux in Pulmonary Arterial Hypertension

NCT07737522 on ClinicalTrials.gov · last registry update 2026-07-30

A small phase 2 — 32 participants, against a typical 110. Due to report 1 October 2028. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for hypertension — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: NOT_YET_RECRUITING
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Imperial College London
Sponsor type: Other
Enrollment: 32
Started: 2026-10-01
Primary completion: 2028-10-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in the phosphocreatine-to-adenosine triphosphate (31PCr/ATP) ratio between baseline and follow up in response to treatment with GLP-1 agonist

Conditions studied

Pulmonary Arterial Hypertension

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.